BRCA1 and breast carcinoma: To date, the application of PARP inhibitors to TNBC has mainly been based on the morphologic-molecular similarities with BRCA1-mutated breast cancers and on the results from clinical studies, but not on PARP-related pathways or on the status of PARP proteins.